What makes PsiOxus’ Oncolytic Virus EnAd effective at targeting metastatic cancer cells?




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: What makes PsiOxus’ Oncolytic Virus EnAd effective at targeting metastatic cancer cells?
Released on: March 03, 2016. © PharmaVentures Ltd
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
In This Episode:
    Enadenotucirev (EnAd) is an intravenous therapy, currently in Phase I and II clinical trials for the systemic treatment of metastatic cancers.
  • Summary
  • Transcript
  • Participants
  • Company
Enadenotucirev (EnAd) is an intravenous therapy, currently in Phase I and II clinical trials for the systemic treatment of metastatic cancers. John Beadle, CEO of PsiOxus, describes EnAd’s unique mechanism of action.
Enadenotucirev (EnAd) is an intravenous therapy, currently in Phase I and II clinical trials for the systemic treatment of metastatic cancers. John Beadle, CEO of PsiOxus, describes EnAd’s unique mechanism of action.
Dr John Beadle was Entrepreneur in Residence at Imperial College London, where he helped to establish Myotec Therapeutics as a spin-out business. He became CEO of Myotec in late 2008, rapidly securing seed financing followed by a £5.6 million series A funding round from Imperial Innovations and Invesco Perpetual in early 2010. During this time, John was also Executive Chairman and CEO of Hybrid Biosystems, securing further seed financing for this Oxford based start-up. In 2010, John's leadership of these two private companies led to their combination to form PsiOxus Therapeutics Ltd. John was previously the co-founder of the vaccine company PowderMed. In 2004 he helped to raise £20 million from leading UK and US Venture Capital Funds and was then Chief Medical Officer and board director leading to the trade sale of PowderMed to Pfizer for over US$300 million in 2006. John has previously held roles at PowderJect, Pfizer and Glaxo SmithKline where he was most recently VP of Global Medical Operations. John was trained in Medicine at the University of Witwatersrand and received his MBA with distinction from the London Business School.
Psioxus
PsiOxus Therapeutics Ltd develops novel therapeutics for serious diseases. We are an Oxford, London and Berlin based development stage biotechnology company with world leading scientists and a highly experienced management team. Our approach is to combine different elements including small molecules, viruses, polymers and other macro-molecules to produce novel patent protected therapeutics. We deliberately target diseases that result in significant associated global morbidity and mortality, with a particular focus upon cancer